Verona Pharma Stock (NASDAQ:VRNA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$38.09

52W Range

$11.39 - $40.13

50D Avg

$32.92

200D Avg

$21.67

Market Cap

$3.18B

Avg Vol (3M)

$1.01M

Beta

0.42

Div Yield

-

VRNA Company Profile


Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

GB

Employees

79

IPO Date

Apr 28, 2017

Website

VRNA Performance


VRNA Financial Summary


Dec 23Dec 22Dec 21
Revenue-$458.00K$40.00M
Operating Income$-54.84M$-66.12M$-73.31M
Net Income$-54.37M$-68.70M$-55.57M
EBITDA$-54.84M$-62.66M$-57.04M
Basic EPS-$-0.12$-0.09
Diluted EPS-$-0.12$-0.09

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 04, 24 | 11:47 AM
Q2 24Aug 08, 24 | 1:15 PM
Q1 24May 09, 24 | 12:00 AM

Peer Comparison


TickerCompany
AKROAkero Therapeutics, Inc.
XFORX4 Pharmaceuticals, Inc.
IDYAIDEAYA Biosciences, Inc.
MREOMereo BioPharma Group plc
APLSApellis Pharmaceuticals, Inc.
DAWNDay One Biopharmaceuticals, Inc.
VTYXVentyx Biosciences, Inc.
SNDXSyndax Pharmaceuticals, Inc.
TERNTerns Pharmaceuticals, Inc.
VKTXViking Therapeutics, Inc.
INZYInozyme Pharma, Inc.
MLTXMoonLake Immunotherapeutics
ABOSAcumen Pharmaceuticals, Inc.
PTGXProtagonist Therapeutics, Inc.
MDGLMadrigal Pharmaceuticals, Inc.
AMLXAmylyx Pharmaceuticals, Inc.